-
公开(公告)号：US20240066113A1
公开(公告)日：2024-02-29
申请号：US18029758
申请日：2022-04-12
Applicant: ACADEMIA SINICA
Inventor： Chi-Huey WONG , Chung-Yi WU , Che MA , Chen-Yu FAN
IPC: A61K39/215 , A61K9/127 , A61P31/14 , C07K14/165
CPC classification number: A61K39/215 , A61K9/127 , A61P31/14 , C07K14/165 , A61K2039/545
Abstract: The present invention relates to the mRNA vaccine of coronavirus spike protein with deletion of glycosites in the receptor binding domain (RBD), the subunit 1 (S1) domain, or the subunit 2 (S2) domain, or a combination thereof. The vaccine elicits broadly protective immune responses coronavirus and variants thereof.
-
公开(公告)号：US20170283878A1
公开(公告)日：2017-10-05
申请号：US15376598
申请日：2016-12-12
Applicant: Academia Sinica
Inventor： Chi-Huey WONG , Chung-Yi WU , Sarah K.C. CHEUNG , Po-Kai CHUANG , Tsui-Ling HSU
IPC: C12Q1/68 , G01N33/574 , G01N33/50
CPC classification number: C12Q1/6886 , A61K2039/505 , C07K16/18 , C07K16/3053 , C07K2317/21 , C07K2317/24 , C07K2317/622 , C07K2317/734 , C07K2317/92 , C12Q2600/118 , C12Q2600/158 , C12Y204/01 , G01N33/5073 , G01N33/57407 , G01N33/57492 , G01N2333/70585 , G01N2333/70596 , G01N2333/91097 , G01N2405/10 , G01N2500/04 , G01N2500/10 , G01N2800/52
Abstract: The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.
-
公开(公告)号：US20160193310A1
公开(公告)日：2016-07-07
申请号：US14392341
申请日：2014-06-26
Applicant: Chi-Huey WONG , Chung-Yi WU , Hong-Yang CHUANG , Chien-Tai REN , ACADEMIA SINICA
Inventor： Chi-Huey WONG , Chung-Yi WU , Hong-Yang CHUANG , Chien-Tai REN
CPC classification number: A61K39/0011 , A61K31/7028 , A61K39/385 , A61K49/00 , A61K2039/575 , A61K2039/585 , A61K2039/6037 , A61K2039/627 , C07H15/04 , C07H15/10 , C07H15/14 , C07K14/4748
Abstract: Described herein are synthetic glycan conjugates, immmunogenic compositions thereof, vaccines thereof, and kits thereof. The present invention further provides methods of using the synthetic glycan conjugates, immunogenic compositions, or vaccines thereof to treat and/or prevent and/or diagnose proliferative diseases such as cancer. The provided glycan conjugate comprises a carrier and a glycan moiety of Formula (I-i) or Formula (I-ii): (structurally represented).
Abstract translation: 本文描述的是合成聚糖缀合物，其免疫原性组合物，其疫苗及其试剂盒。 本发明还提供了使用合成聚糖缀合物，免疫原性组合物或其疫苗来治疗和/或预防和/或诊断增殖性疾病如癌症的方法。 所提供的聚糖缀合物包含式（I-i）或式（I-ii）的载体和聚糖部分：（结构上表示）。
-
公开(公告)号：US20170275389A1
公开(公告)日：2017-09-28
申请号：US15505763
申请日：2015-08-21
Applicant: ACADEMIA SINICA
Inventor： Chi-Huey WONG , Chung-Yi WU , Hsin-Yu LEE
CPC classification number: C08B37/0024 , A61K39/0011 , A61K39/0016 , A61K47/36 , A61K47/6415 , A61K47/646 , A61K2039/555 , A61K2039/6037 , C07H3/06 , C07K14/33 , C07K14/34 , G01N2333/4728
Abstract: This disclosure includes an immunogenic composition containing (a) a glycan conjugate including a carrier and one or more glycans, wherein each of the one or more glycans is conjugated with the carrier through a linker, and optionally (b) an adjuvant. The one or more glycan is each a Globo H derivative.
-
公开(公告)号：US20160289340A1
公开(公告)日：2016-10-06
申请号：US15011543
申请日：2016-01-30
Applicant: Academia Sinica
Inventor： Chi-Huey WONG , Tsui-Ling HSU , Yi-Wei LOU , Chih-Wei LIN , Shih-Chi YEH , Chung-Yi WU , Han-Chung WU , Han-Chung WU
IPC: C07K16/44
CPC classification number: C07K16/44 , A61K2039/505 , C07K16/18 , C07K16/3053 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/622 , C07K2317/732 , C07K2317/734 , C07K2317/92 , G01N33/57407 , G01N2800/52
Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.
Abstract translation: 本文公开了包含与globo H，SSEA3和SSEA-4结合的抗体或其抗原结合片段的药物组合物及其使用方法。 使用的方法包括但不限于癌症治疗和诊断。 本公开的抗体可以结合某些癌细胞表面。 本文公开的抗体的示例性靶标可以包括癌，例如脑，皮肤，骨，肺，乳腺，食道，胃，肝，胆管，胰腺，结肠，肾，子宫颈，卵巢和/或前列腺癌中的那些。
-
Patent Agency Ranking
公开(公告)号：US20230074185A1
公开(公告)日：2023-03-09
申请号：US17933832
申请日：2022-09-20
Applicant: Academia Sinica
Inventor： Chi-Huey WONG , Chung-Yi WU
Abstract: Immunogenic compositions comprising hemagglutinin (HA) variants and/or neuraminidase (NA) variants, which may be contained in an influenza A virus, and uses thereof for eliciting immune responses against influenza A virus.
-
公开(公告)号：US20210332146A1
公开(公告)日：2021-10-28
申请号：US17211619
申请日：2021-03-24
Applicant: ACADEMIA SINICA
Inventor： Chi-Huey WONG , Chung-Yi WU , Ming-Hung Tsai
Abstract: The present disclosure relates to a novel class of anti-CD20 monoclonal antibodies comprising a homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-CD20 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.
-
公开(公告)号：US20190194303A1
公开(公告)日：2019-06-27
申请号：US16150164
申请日：2018-10-02
Applicant: Academia Sinica
Inventor： Chi-Huey WONG , Chung-Yi WU
CPC classification number: C07K16/18 , C07K2317/41 , C07K2317/50 , C12P21/005 , C12Y204/01 , C12Y204/99003
Abstract: Methods for making modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Antibodies comprising Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc regions conjugated with homogeneous glycoforms of monosaccharides and trisaccharides, are provided. Methods of preparing human antibodies with modified Fc using glycan engineering, are provided.
-
9.发明申请COMPOSITIONS AND METHODS RELATING TO UNIVERSAL GLYCOFORMS FOR ENHANCED ANTIBODY EFFICACY 审中-公开与通用胶囊相关的组合物和方法，以提高抗体效能公开(公告)号：US20160280794A1
公开(公告)日：2016-09-29
申请号：US15011544
申请日：2016-01-30
Applicant: Academia Sinica
Inventor： Chi-Huey WONG , Chung-Yi WU , Che MA , Han-Chung WU
CPC classification number: C07K16/30 , A61K45/06 , C07K16/1018 , C07K16/18 , C07K16/241 , C07K16/2887 , C07K16/32 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/622 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C12N9/24 , C12P21/005 , C12Y302/01 , C12Y302/01051
Abstract: The present disclosure relates to compositions and methods of use comprising antibodies or binding fragments thereof further comprising universal Fc glycoforms.
Abstract translation: 本公开涉及包含抗体或其结合片段的组合物和使用方法，其还包含通用Fc糖形式。
-
公开(公告)号：US20150344587A1
公开(公告)日：2015-12-03
申请号：US14723181
申请日：2015-05-27
Applicant: Academia Sinica
Inventor： Chi-Huey WONG , Chung-Yi WU
IPC: C07K16/40 , C12P21/00 , A61K39/395 , C07K16/28 , A61K31/517
CPC classification number: C07K16/40 , A61K31/517 , A61K39/3955 , C07K16/283 , C07K16/32 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/40 , C07K2317/41 , C07K2317/732 , C07K2317/92 , C12P21/005 , C12Y302/01 , C12Y302/01051
Abstract: The present disclosure relates to a novel class of anti-HER2 monoclonal antibodies comprising a homogeneous population of anti-HER2 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-HER2 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.
Abstract translation: 本公开涉及一类新的抗HER2单克隆抗体，其包含在Fc上具有相同N-聚糖的均匀抗HER2 IgG分子群。 本发明的抗体可以通过Fc糖工程从抗HER2单克隆抗体产生。 重要的是，本发明的抗体具有改善的治疗价值，与尚未糖基化的相应单克隆抗体相比，具有增加的ADCC活性和增加的Fc受体结合亲和力。
-
-
-
-
-
-
-
-
-
Search Results
25
records
(took 0.056 seconds)
